A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Conditions

Diseases Of The Digestive System

What is the purpose of this trial?

This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.

  • Trial with
    AbbVie Inc.
  • Start Date
    10/30/2017
  • End Date
    04/29/2027
Trial Image

For more information about this study, contact:

Elizabeth Ruggiero

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

  • Last Updated
    06/22/2018
  • Study HIC
    #1506016096REG